Foghorn Therapeutics Inc. (NASDAQ: FHTX) is a Healthcare company (Biotechnology) with a market capitalization of $110M. The Maz Rating grades it against the other companies in its sector.
Foghorn Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.83, Foghorn Therapeutics Inc. trades at 25.4x trailing earnings and 0.9x sales, with an EV/EBITDA of 6.5. Over the last twelve months it generated about $116M of revenue and $4M of net income. It runs a gross margin of 99.1%, an operating margin of 5.9% and a net margin of 8.4%. It shows return on equity of -14.2%, return on invested capital of 4.2% and a free cash flow yield of -78.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 4.24. Over the past 52 weeks the share price ranged from $1.73 to $7.61, with a beta of 3.21.
Foghorn Therapeutics Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 8 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.